CytomX Therapeutics price to book ratio CTMX

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 1.7×
10-year median: 4.8×
Against its 10-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.2× to 28.1×
Peer median: 1.9×

CytomX Therapeutics' price to book ratio is 1.7× as of Oct 23, 2026.

That is below its ten-year median of 4.8×, lower than on 97% of days in the last ten years.

Over that time it ranged from 1.2× in Jul 2022 to 28.1× in Mar 2018.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.7×	1.6×	9.0×
2025	6.9×	2.6×	8.9×
2024	n/m a value too high to mean anything
2023	3.9×	3.9×	6.6×
2022	3.7×	1.2×	4.2×
2021	2.5×	2.3×	12.2×
2020	6.3×	3.7×	10.0×
2019	4.7×	2.8×	5.4×
2018	4.3×	3.8×	28.1×
2017	17.8×	4.5×	19.2×
2016	4.5×	3.0×	5.6×

Against its peers

Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.

Company	Price to book ratio
CTMXCytomX Therapeutics	1.7×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
NATRNatures Sunshine Products	1.3×
OMEROmeros	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on CytomX Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.